复杂的亡信号通路对癌细胞对治疗敏感性的影响
Ryungsa Kim1, Takanori Kin2, William T Beck3
1Department of Breast Surgery, Hiroshima Mark Clinic, 1-4-3F, 2-Chome Ohte-machi, Naka-ku, Hiroshima 730-0051, Japan.
Cancers
|March 13, 2024
概括
抗癌药物通过各种途径触发亡,包括c-Jun/AP-1/p53和Gadd153途径,影响耐药性. 准像Bcl-2这样的亡基因可以提高治疗效率.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 细胞死亡信号传递
背景情况:
- 抗癌药物诱导各种细胞死亡机制,包括细胞亡和非细胞亡途径.
- 药物诱导的亡信号通路在敏感癌细胞和耐药癌细胞之间有所不同.
- 在多抗药性白血病中,c-Jun/AP-1/p53通路发生变化,影响细胞死亡.
研究的目的:
- 审查参与抗癌药物诱导细胞死亡的信号通路.
- 讨论药物耐药癌细胞中这些途径的改变.
- 通过调节细胞死亡途径,探索增强抗癌药物疗效的策略.
主要方法:
- 对抗癌症药物诱导的细胞死亡现有文献的综述.
- 对信号通路的分析,包括c-Jun/AP-1,p53,Gadd153和caspase级联.
- 检查内在和外在亡途径的作用.
- 对抗apoptotic基因 (例如,BCL-2) 和它们的调制的研究.
主要成果:
- 抗癌药物通过c-Jun/AP-1和Gadd153途径诱导细胞亡,无论p53状态如何.
- Gadd153的诱导涉及线粒体透和内质网膜压力.
- 亡诱导利用内在 (细胞染色体c) 和外在途径,涉及酶依赖和独立的机制.
- 针对像Bcl-2这样的抗瘤基因和调节Bcl-xS可以提高抗药细胞中的药物敏感性.
结论:
- 通过向特定的细胞死亡信号通路,可以提高抗癌药物的疗效.
- 调节亡,特别是通过抗亡基因,提供了对抗药物耐药性的有希望的策略.
- 需要进一步的研究来阐明自在癌症治疗中的作用.
相关概念视频
Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
The Intrinsic Apoptotic Pathway
6.5K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.5K
The Extrinsic Apoptotic Pathway
6.4K
The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
6.4K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Adaptive Mechanisms in Cancer Cells
5.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K


